NCT06941246Completed
Prolactin Levels in Type 2 Diabetic Patients With Stage III Periodontitis
Gingival Crevicular Fluid Levels of Prolactin Hormone in Type 2 Diabetic Patients With Stage III Periodontitis Before and After Non-Surgical Treatments
Source: ClinicalTrials.gov · Last updated 23 Apr 2025
Brief summary (registry, in English)
evaluate the role of prolactin hormone in the pathogenesis of periodontitis by assessing its local gingival levels and assess clinical parameters in patients who have type two diabetes
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 12 Apr 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 1 Jan 2025
- Lead sponsor
- Faculty of Dental Medicine for Girls
- Diseases
- Type 2 diabetes
- NCT number
- NCT06941246
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 1 Oct 2024 to the primary completion date, 1 Jan 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any type of previous periodontal treatment (surgical or non-surgical) in the preceding 6 months
Other illness
- Any known systemic disease
Other
- Pregnancy or lactation
- Smoking (former or current)
Who the study is looking for
- Age range from 18 to 60 years
- Stage III periodontitis
- Type 2 diabetes
- Only patients signing informed written consents
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sara Ibrahim Hussein Eid Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.